PHIO · XBRL financial data
Phio Pharmaceuticals financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PHIO's year ends in late December)
| In thousands of dollars | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 21 | 0 | — | — | — | — |
| Research and development | 4,300 | 4,431 | 7,012 | 6,332 | 3,643 | 4,618 |
| General and administrative | 4,708 | 4,362 | 4,450 | 4,366 | 3,744 | 4,602 |
| Total operating expenses | 9,008 | 8,793 | 11,462 | 10,824 | 7,387 | 9,220 |
| Operating income (loss) | (8,987) | (8,793) | (11,462) | (10,824) | (7,387) | (9,220) |
| Other income (expense) | — | — | — | — | 6 | 2 |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (8,908) | (8,794) | (11,480) | (10,826) | (7,150) | (8,698) |
| Earnings per share, basic USD per share | — | — | (10.10) | (5.20) | (9.08) | (1.45) |
| Earnings per share, diluted USD per share | — | — | (10.10) | (5.20) | (9.08) | — |
| Weighted average shares, basic thousands of shares | — | — | 1,137 | 2,084 | 787 | 5,984 |
| Weighted average shares, diluted thousands of shares | — | — | 1,137 | 2,084 | 787 | — |
- † Share count changed about 1/3 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (PHIO's year ends in late December)
| In thousands of dollars | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6,984 | 14,294 | 11,831 | 8,490 | 5,382 | 21,031 |
| Prepaid and other current assets | 316 | 870 | 615 | 832 | 354 | 445 |
| Total current assets | 7,300 | 15,164 | 12,446 | 9,322 | 5,736 | 21,476 |
| Property and equipment, net | 210 | 157 | 183 | 6 | 2 | 11 |
| Right-of-use asset | 511 | 400 | 161 | 33 | 0 | — |
| Total assets | 8,039 | 15,739 | 12,814 | 9,364 | 5,738 | 21,487 |
| Accounts payable | 809 | 728 | 779 | 657 | 253 | 435 |
| Accrued liabilities | 964 | 1,352 | 1,025 | 942 | 762 | 905 |
| Total current liabilities | 1,880 | 2,196 | 1,939 | 1,634 | 1,015 | — |
| Long-term debt | 0 | 231 | — | — | — | — |
| Lease liability, non-current | 411 | 295 | 35 | 0 | 0 | — |
| Total liabilities | 2,291 | 2,722 | 1,974 | 1,634 | 1,015 | 1,340 |
| Accumulated deficit | (94,819) | (103,613) | (128,380) | (139,206) | (146,356) | (155,054) |
| Total stockholders' equity | 5,748 | 13,017 | 10,838 | 7,730 | 4,723 | 20,147 |
| Total liabilities and equity | 8,039 | 15,739 | 12,814 | 9,364 | 5,738 | 21,487 |
| Common shares outstanding (cover page) thousands of shares | 2,868 | 13,532 | 13,535 | 4,592 | 4,778 | 11,617 |
- † Share count changed about 1/3 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (PHIO's year ends in late December)
| In thousands of dollars | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (8,908) | (8,794) | (11,480) | (10,826) | (7,150) | (8,698) |
| Stock-based compensation | 300 | 136 | 414 | 303 | 147 | 481 |
| Depreciation and amortization | 67 | 72 | 71 | 56 | 2 | 3 |
| Net cash from operating activities | (8,645) | (8,802) | (12,129) | (10,749) | (7,112) | (7,979) |
| Purchases of property and equipment | 72 | 19 | 121 | 5 | 1 | 12 |
| Net cash from investing activities | (72) | (19) | (121) | (5) | 8 | (12) |
| Proceeds from issuing equity | 708 | 12,087 | — | 7,452 | 4,002 | 20,600 |
| Net cash from financing activities | 772 | 16,131 | (26) | 7,413 | 3,996 | 23,640 |
| Net change in cash | — | — | — | — | (3,108) | 15,649 |
- † Share count changed about 1/3 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Phio Pharmaceuticals | 12,996 | not reported | (4,035)* | 11.6M | 3.2 quarters | 10-QJun 30, 2026 |
| Palisade Bio | 125,172 | 500 | (7,603)* | 174.3M | 16.5 quarters | 10-QJun 30, 2026 |
| Citius Pharmaceuticals | 17,008 | 1,494 | (8,678)* | 27.5M | 2.0 quarters | 10-QJun 30, 2026 |
| Cocrystal Pharma | 2,169 | 105 | (2,516)* | 19.3M | 0.9 quarters | 10-QJun 30, 2026 |
| Brainstorm Cell Therapeutics | 22 | not reported | (895) | 11.0M | 0.0 quarters | 10-QJun 30, 2026 |
| Kiora Pharmaceuticals | 7,077 | not reported | (1,892)* | 4.4M | 8.9 quarters | 10-QJun 30, 2026 |
| Cypherpunk Technologies | 7,624 | not reported | (2,692)* | 107.8M | 2.8 quarters | 10-QJun 30, 2026 |
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.